

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
28 March 2019 (28.03.2019)



(10) International Publication Number
WO 2019/058393 A1

(51) International Patent Classification:

C07D 471/04 (2006.01) C07D 498/04 (2006.01)
A61K 31/4188 (2006.01) A61P 29/00 (2006.01)
A61K 31/4985 (2006.01)

(21) International Application Number:

PCT/IN2018/050614

(22) International Filing Date:

20 September 2018 (20.09.2018)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

201741033768 22 September 2017 (22.09.2017) IN

(71) Applicant: JUBILANT BIOSYS LIMITED [IN/IN];

#96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Karnataka, Bangalore 560022 (IN).

(72) Inventors: HALLUR, Gurulingappa; #96, Industrial

Suburb, 2nd Stage, Yeshwanthpur, Bangalore 560 022 (IN). DURAISWAMY, Athisayamani Jeyaraj; #96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Bangalore 560 022 (IN). PURRA, Buchi Reddy; #96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Bangalore 560 022 (IN). RAO, N.V.S.K.; #96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Bangalore 560 022 (IN). RAJAGOPAL, Sridharan; #96, Industrial Suburb, 2nd Stage, Yeshwanthpur, Bangalore 560022 (IN).

(74) Agent: LAKSHMIKUMARAN, Malathi et al.; B6/10,

Safdarjung Enclave, New Delhi 110029 (IN).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,

HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

Published:

— with international search report (Art. 21(3))
— in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: HETEROCYCLIC COMPOUNDS AS PAD INHIBITORS



(57) Abstract: Heterocyclic compounds of Formula (I), (II), and (III) are described herein along with their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof. The compounds described herein, their polymorphs, stereoisomers, prodrugs, solvates, co-crystals, intermediates, pharmaceutically acceptable salts, and metabolites thereof are PAD4 inhibitors and may be useful in the treatment of various disorders, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, cutaneous lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, multiple sclerosis and psoriasis.

WO 2019/058393 A1